Bryce Point Capital LLC Takes $1.24 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Bryce Point Capital LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, HoldingsChannel reports. The firm purchased 3,522 shares of the biotechnology company’s stock, valued at approximately $1,243,000.

Several other institutional investors also recently modified their holdings of UTHR. Signaturefd LLC lifted its holdings in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock worth $234,000 after buying an additional 30 shares during the period. Parallel Advisors LLC lifted its stake in shares of United Therapeutics by 2.8% in the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 30 shares during the period. Great Lakes Advisors LLC boosted its holdings in United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after acquiring an additional 31 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after purchasing an additional 33 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in United Therapeutics by 0.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. This trade represents a 79.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,500 shares of company stock worth $26,134,500. Corporate insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on UTHR shares. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $312.26 on Thursday. United Therapeutics Co. has a one year low of $227.75 and a one year high of $417.82. The company has a market cap of $14.02 billion, a PE ratio of 13.71, a PEG ratio of 0.97 and a beta of 0.64. The firm has a 50-day moving average of $336.64 and a 200-day moving average of $355.09.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business posted $4.36 earnings per share. On average, equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.